Valeant raises cash portion of Allergan offer; bid values company at US$54.5B

MONTREAL – Valeant Pharmaceuticals International, Inc. (TSX:VRX) raised its offer for Allergan Inc. for the second time in less than a week.

The company is now offering US$72 in cash and 0.83 shares of Valeant common stock for each Allergan share.

That’s up from an offer of US$58.30 and 0.83 of a Valeant share made just days ago.

The new bid values Allergan’s shares at about US$183.25 per share and the company at roughly US$54.5 billion. Allergan shares were trading up $10.47 at $168.97.

Under the bid, Allergan’s largest shareholder, Bill Ackman’s Pershing Square Capital Management, has also agreed to accept less for its Allergan shares than other shareholders.

Pershing Square, which holds a 9.7 per cent stake, has agreed to forgo any cash and receive 1.22659 Valeant shares for each Allergan share.

News from © The Canadian Press, . All rights reserved.
This material may not be published, broadcast, rewritten or redistributed.

The Canadian Press

The Canadian Press is Canada's trusted news source and leader in providing real-time, bilingual multimedia stories across print, broadcast and digital platforms.